TLRY
Tilray Brands, Inc. Health Care Medicinal Chemicals & Botanical Products Russell 3000
$2.53Close
$333.2MMarket cap
$2.53 – $13.9452-week range
Early-januaryNext report · estimated
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 1 · weaker than 99% of stocks over 12 months
- Far from its high 82% below its 52-week high
- Distribution down-day volume 2.1× up-day volume over 50 sessions
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
82%
1wk
down 10.0%
price change
1mo
down 32.5%
price change
12-month return
down 80%
market up 11% ·
its own down 92%
F-score
3 / 9
Weak
Altman Z
-2.19
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.2×
price / book
Earnings yield
down 27.7%
EBIT / enterprise value
Cheaper than
35%
of the market · expensive
Revenue growth
up 11%
year on year
EPS growth
—
latest quarter
Sales growth
up 23%
latest quarter · -3 pts
ROE
down 8%
return on equity
Free cash margin
down 8%
-$69.1M FCF
D/E
0.07
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- took on more long-term debt
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitability improving
- profits backed by cash
- assets working harder
Trade setup
ATR%
6.2%
$0.16 a day · 2×ATR $2.22
RS
1 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
0.47
50 sessions
Implied move
—
no scheduled report
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 24.1% over the year, from 106m to 132m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Oct 8, 2026
Results reaction
Oct 8, 2026-5% vs market2 sessions after results
Financials
- Gross 28%
- Net -13%
- Free cash -8%
- Cash
- Long-term debt
| FY2021May 31, 2021 | FY2022May 31, 2022 | FY2023May 31, 2023 | FY2024May 31, 2024 | FY2025May 31, 2025 | FY2026May 31, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $513.1M | $628.4M | $627.1M | $788.9M | $821.3M | $915.5M |
| Gross margin | 24% | 19% | 23% | 28% | 29% | 28% |
| Operating income | -$132.2M | -$610.4M | -$1.4B | -$174.7M | -$2.3B | -$63.0M |
| Net income | -$367.4M | -$476.8M | -$1.5B | -$245.0M | -$2.2B | -$121.4M |
| Net margin | -72% | -76% | -232% | -31% | -266% | -13% |
| Earnings per share | -$1.36 | -$0.99 | -$2.35 | -$3.30 | -$24.56 | -$1.09 |
| Free cash flow | -$83.6M | -$211.3M | -$12.9M | -$60.2M | -$127.5M | -$69.1M |
| Free cash margin | -16% | -34% | -2% | -8% | -16% | -8% |
| Cash | $488.5M | $415.9M | $206.6M | $228.3M | $221.7M | $226.0M |
| Long-term debt | $167.5M | $117.9M | $395.4M | $129.9M | — | $120.4M |
| Shareholders' equity | $4.5B | $4.4B | $3.3B | $3.4B | $1.5B | $1.6B |
| Shares outstanding | 446.44m | 532.67m | 656.66m | 831.93m | 106.07m | 131.68m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 8, 2026 | Quarterly ↗ | Aug 31, 2026 | 38d |
| Jul 28, 2026 | Annual ↗ | May 31, 2026 | 58d |
| Apr 1, 2026 | Quarterly ↗ | Feb 28, 2026 | 32d |
| Jan 8, 2026 | Quarterly ↗ | Nov 30, 2025 | 39d |
| Oct 9, 2025 | Quarterly ↗ | Aug 31, 2025 | 39d |
| Jul 29, 2025 | Annual ↗ | May 31, 2025 | 59d |
| Apr 8, 2025 | Quarterly ↗ | Feb 28, 2025 | 39d |
| Jan 10, 2025 | Quarterly ↗ | Nov 30, 2024 | 41d |
| Oct 10, 2024 | Quarterly ↗ | Aug 31, 2023 | 406d |
| Oct 10, 2024 | Quarterly ↗ | Aug 31, 2024 | 40d |
| Jul 30, 2024 | Annual ↗ | May 31, 2024 | 60d |
| Apr 9, 2024 | Quarterly ↗ | Feb 29, 2024 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 8, 2026 | Results ↗ |
| Sep 14, 2026 | Unregistered share sale ↗ |
| Aug 10, 2026 | Unregistered share sale ↗ |
| Jul 28, 2026 | Results ↗ |
| Jun 30, 2026 | Unregistered share sale ↗ |
| Jun 9, 2026 | Unregistered share sale ↗ |
| Apr 21, 2026 | Other events ↗ |
| Apr 15, 2026 | Material agreement ↗ |
| Apr 15, 2026 | Unregistered share sale ↗ |
| Apr 1, 2026 | Results ↗ |
| Mar 2, 2026 | Material agreement · Acquisition or disposal · Other events ↗ |
| Jan 8, 2026 | Results ↗ |